<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">Colorectal cancer</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>) is one of the most common <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e>; however, the development of drugs to treat the condition has reached a plateau </plain></SENT>
<SENT sid="1" pm="."><plain><z:chebi fb="0" ids="52717">Bortezomib</z:chebi> (<z:chebi fb="0" ids="52717">PS-341</z:chebi>, <z:chebi fb="0" ids="52717">Velcade</z:chebi>Â®) is a <z:chebi fb="0" ids="52726">proteasome inhibitor</z:chebi> approved for the treatment of <z:e sem="disease" ids="C0376545" disease_type="Neoplastic Process" abbrv="">hematological malignancies</z:e>, including <z:hpo ids='HP_0006775'>multiple myeloma</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>A few trials of <z:chebi fb="0" ids="52717">bortezomib</z:chebi>, alone or in combination chemotherapy, for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> patients have been reported; however, the results were largely inconclusive </plain></SENT>
<SENT sid="3" pm="."><plain>This may be related to a lack of understanding of the drug's mechanism of action </plain></SENT>
<SENT sid="4" pm="."><plain>Although <z:chebi fb="0" ids="52717">bortezomib</z:chebi> is reported to induce <z:mpath ids='MPATH_3'>apoptosis</z:mpath> and cell cycle arrest in various human <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> cells, the inhibitory mechanism involved is not clear </plain></SENT>
<SENT sid="5" pm="."><plain>In this study, the effect of <z:chebi fb="0" ids="52717">bortezomib</z:chebi> as a treatment for human <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> was examined in vitro using three <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> cell lines </plain></SENT>
<SENT sid="6" pm="."><plain><z:chebi fb="0" ids="52717">Bortezomib</z:chebi> induced G2-M arrest in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> cells </plain></SENT>
<SENT sid="7" pm="."><plain>Investigation of G2-M phase-related cell cycle proteins involved in the response to <z:chebi fb="0" ids="52717">bortezomib</z:chebi> revealed that the <z:hpo ids='HP_0001251'>ataxia</z:hpo> <z:hpo ids='HP_0001009'>telangiectasia</z:hpo> mutated (ATM)-cell cycle checkpoint kinase 1 (CHK1) pathway, but not ATM and Rad3-related (ATR), was activated, resulting in the inactivation of cdc2 </plain></SENT>
<SENT sid="8" pm="."><plain><z:chebi fb="0" ids="52717">Bortezomib</z:chebi> caused an increase in intracellular reactive oxygen species (ROS) and treatment with the ROS scavenger NAC inhibited phosphorylation of ATM leading to a decrease in the number of cells in G2-M phase </plain></SENT>
<SENT sid="9" pm="."><plain>Thus, increased ROS levels after exposure to <z:chebi fb="0" ids="52717">bortezomib</z:chebi> resulted in ATM phosphorylation </plain></SENT>
<SENT sid="10" pm="."><plain>In addition, knockdown of endogenous ATM by <z:chebi fb="40" ids="33697">RNA</z:chebi> interference resulted in decreased sensitivity to <z:chebi fb="0" ids="52717">bortezomib</z:chebi> </plain></SENT>
<SENT sid="11" pm="."><plain>These results suggest that <z:chebi fb="0" ids="52717">bortezomib</z:chebi> induces G2-M arrest through ROS-inducible ATM phosphorylation and demonstrate that <z:chebi fb="0" ids="52717">bortezomib</z:chebi> is a potential candidate for further investigations in the treatment for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> patients </plain></SENT>
</text></document>